- Advanced search
- Guide to IMMUNOPHARMACOLOGY Portal
|International Nonproprietary Names|
|REGN-1193 | REGN1193|
|Crotedumab (REGN1193) is a fully human IgG4 monoclonal antibody that functionally antagonises activity of the glucagon receptor (GCGR) in vitro . REGN1193 was investigated as a potential therapy for type 2 diabetes mellitus.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
This mAb is no longer included in Regeneron's development pipeline (access their pipeline webpage here).
|GtoPdb PubChem SID||340590244|
|Search PubMed clinical trials||crotedumab|
|Search PubMed titles||crotedumab|
|Search PubMed titles/abstracts||crotedumab|